Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of nivolumab plus docetaxel versus placebo plus docetaxel in metastatic castration-resistant prostate cancer
MOH_2020-02-16_008650Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Nivolumab arm with Placebo control arm (2 arms). Primary endpoints: Radiographic progression-free survival and Overall survival. Started Jan 2020; status: active, not recruiting.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on MOH_2020-02-16_008650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-02-16_008650.